Singapore-based ASLAN Pharmaceuticals, a biotechnology company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, will conduct a competitive auction and public offer of common shares for its initial listing on Taipei Exchange (TPEx).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
